<?xml version="1.0" encoding="UTF-8"?>
<p>UT
 <sup>3</sup>C received technical support from SSS through a grant of the Bill and Melinda Gates Foundation. 
 <bold>The BCPP trial</bold> is supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement U01 GH000447. 
 <bold>The </bold>
 <italic>
  <bold>Max</bold>
 </italic>
 <bold>ART trial</bold> is supported by the Dutch Postcode Lottery, the Embassy of the Kingdom of the Netherlands in Mozambique, British Colombia Centre of Excellence in Canada, Mylan, and Médecins Sans Frontières. 
 <bold>The PopART trial</bold> is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), United States National Institutes of Health (NIH), and is funded by the NIAID, the National Institute of Mental Health, the Office of the United States Global AIDS Coordinator, the Bill and Melinda Gates Foundation and the NIH. 
 <bold>The SEARCH trial</bold> sponsors, partners and advisors include the NIAID of NIH, PEPFAR, the Ministries of Health of Uganda and Kenya, the Bill and Melinda Gates Foundation, the WHO, UNAIDS, the World Bank, the Global Fund for HIV, TB and Malaria, the Infectious Diseases Research Collaboration (IDRC), the Kenya Medical Research Institute (KEMRI), and Gilead Sciences, Inc. The research reported in the publication was funded by Division of AIDS, NIAID of NIH under award number U01AI099959 and in part by the PEPFAR and Gilead Sciences. 
 <bold>The ANRS TasP trial</bold> was sponsored by the French National Institute of Health and Medical Research‐French National Agency for AIDS and Viral Hepatitis Research (Inserm−ANRS), and was funded by the ANRS, the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, the International Initiative for Impact Evaluation (3iE), Gilead Sciences, Inc and MERCK &amp; Co., Inc.
</p>
